化疗辅助吡柔比星治疗老年恶性淋巴瘤患者50例效果分析

Chemotherapy plus pirarubicin in treatment of malignant lymphoma in the elderly:an analysis of 50 cases

目的：观察使用吡柔比星辅助化疗方案治疗老年人恶性淋巴瘤的疗效及不良反应。方法搜集浙江省丽水市中心医院2011年1月～2013年1月收治的50例非霍奇金淋巴瘤老年患者（60岁以上），按照随机数字表分为对照组（n=25）和实验组（n=25）。实验组给予CTOP化疗方案，对照组给予标准CHOP化疗方案，2组均根据患者具体情况给予止吐、保胃、降压、控制血糖等适当对症治疗。对2组患者给予定期检查，观察骨髓抑制情况，淋巴瘤治疗情况，并发症等指标。结果实验组在治疗后完全缓解的患者为13例，占组内比例为52%，出现部分缓解患者为9例，占组内比例为36%，总有效人数为22，总有效率为88%；对照组在治疗后完全缓解的患者为8例，占组内比例为32%，出现部分缓解患者为5例，占组内比例为20%，总有效人数为13例，总有效率为52%。实验组骨髓抑制情况显著少于对照组（P＜0.05）。结论老年恶性淋巴瘤患者中化疗辅加吡柔比星可提高治疗效果，减少骨髓抑制，减少并发症的发生情况。

Objective To investigate the effects and toxicity of pirarubicin and chemotherapy regimen in treatment of malignant lymphoma in the elderly. Methods 50 cases(over 60 years of age) with non Hodgkin''s lymphoma collected in Lishui Central Hospital of Zhejiang province from January 2011 to January 2013 were randomly divided into control group(n=25)and experimental group(n=25). Experimental group were received CTOP chemotherapy, control group were received the standard CHOP chemotherapy, vomiting, stomach, blood pressure, blood glucose control and other appropriate symptomatic treatment were adopted according to the speciifc circumstances of each patient in both two groups. Regular inspection were given to all patients, and bone marrow suppression, treatment of lymphoma, complications and other indicators were observed. Results Complete remission in experimental group after treatment was 13 cases, accounted for 52%within group, partial remission were 9 cases, accounted for 36%. The total effective number was 22, and the rate was 88%. Complete remission in control group after treatment was 8 cases, accounted for 32%within group, partial remission were 5 cases, accounted for 20%. The total effective number was 13 cases, and the rate was 52%. Bone marrow suppression in experimental group was signiifcantly less than control group (P<0.05). Conclusion Elderly patients with malignant lymphoma in chemotherapy plus pirarubicin can improve the therapeutic effect, reduce bone marrow suppression and complications.